The use of Nifedipine (NI), a dihydropyridine
calcium channel blocker, is limited due to its
poor aqueous solubility. However, NI loaded solid-lipid nanoparticles (NI-SLN)
are known to exhibit suitable pharmacokinetic properties and good
biocompatibility. The present investigation was designed to evaluate the
effects of NI-SLN on glucose homeostasis, lipid metabolism and liver function
in fructose-induced diabetic rats. NI-SLN was prepared by high pressure
homogenization technique followed by lyophilization with trehalose as
cryoprotectant. Diabetes was induced into rats by the administration of
fructose (10%) in drinking water for six weeks. After induction of diabetes,
rats were divided into four groups for the oral ingestion of NI, NI-SLN and/or
vehicles and their effects on blood glucose levels, oral glucose tolerance test
(OGTT), lipid profile, biochemical parameters, electrolytes and histopathology
were observed. Single dose administration and treatment with NI-SLN showed
significant glucose lowering efficacy in fructose-induced diabetic rats.
Although NI and NI-SLN did not alter the fasting blood glucose level in normal
rats, diabetic rats treated with NI-SLN resulted in significant reduction in
glucose level for 24 hr. In OGTT, NI-SLN exhibited significant
antihyperglycemic activity in both normal and diabetic rats. So, NI-SLN has
better glucose lowering efficacy than that of pure NI in diabetic rats. The
survival rates in rats among the treatment groups were 100%. Treatment with
NI-SLN significantly improved lipid profiles than NI alone and the effect was
dose-dependent. Administration of NI-SLN significantly reduced uric acid,
creatinine levels and maintained a good cationic balance. After two weeks of
NI-SLN treatment, hepatocytes regained their
normal architecture, and the beneficial effect could be correlated with the reduction of SGOT and total bilirubin levels.
Therefore, NI-SLN was found to be
useful for the enhancement of bioavailability and exhibited profound
antidiabetic
References
[1]
Kohli, K., Sunny, C., Deepika, D., Saurabh, A. and Roop, K.K. (2010) Self-Emulsifying Drug Delivery Systems: An Approach to Enhance Oral Bioavailability. Drug Discovery Today, 15, 958-965. https://doi.org/10.1016/j.drudis.2010.08.007
[2]
Kim, Y.I., Fluckiger, L., Hoffman, M., Lartaud-Idjouadiene, I., Atkinson, J. and Maincent, T. (1997) The Antihypertensive Effect of Orally Administered Nifedipine-Loaded Nanoparticles in Spontaneously Hypertensive Rats. British Journal of Pharmacology, 120, 399-404. https://doi.org/10.1038/sj.bjp.0700910
[3]
Raemsch, K.D. and Sommer, J. (1983) Pharmacokinetics and Metabolism of Nifedipine. Hypertension, 5, 1118-1124. https://doi.org/10.1161/01.HYP.5.4_Pt_2.II18
[4]
Pabst, G., Lutz, D., Moltz, K.H., Dahmen, W. and Jaeger, H. (1986) Pharmakinetics and Bioavailability of Three Different Galenic Nifedipine Preparations. Arzneimittel-Forschung/Drug Research, 36, 256-260.
[5]
Barman, R.K., Iwao, Y., Funakoshi, Y., Ranneh, A.H., Noguchi, S., Wahed, M.I. and Itai, S. (2014) Development of Highly Stable Nifedipine Solid-Lipid Nanoparticles. Chemical and Pharmaceutical Bulletin, 62, 399-406. https://doi.org/10.1248/cpb.c13-00684
[6]
Barman, R.K., Iwao, Y., Islam, M.R., Funakoshi, Y., Noguchi, S., Wahed, M.I. and Itai, S. (2014) In Vivo Pharmacokinetic and Hemocompatible Evaluation of Lyophilization Induced Nifedipine Solid-Lipid Nanoparticle. Pharmacology & Pharmacy, 5, 455-461. https://doi.org/10.4236/pp.2014.55055
[7]
Funakoshi, Y., Iwao, Y., Noguchi, S. and Itai, S. (2013) Lipid Nanoparticles with No Surfactant Improve Oral Absorption Rate of Poorly Water-Soluble Drug. International Journal of Pharmaceutics, 451, 92-94. https://doi.org/10.1016/j.ijpharm.2013.04.050
[8]
Lithell, H.O. (1991) Effects of Antihypertensive Drugs on Insulin, Glucose and Lipid Metabolism. Diabetes Care, 14, 203-209. https://doi.org/10.2337/diacare.14.3.203
[9]
Navarro-Cid, J., Maeso, R., Perez-Vizcaino, F., Cachofeiro, V., Ruilope, L.M., Tamargo, J. and Lahera, V. (1995) Effects of Losartan on Blood Pressure, Metabolic Alterations, and Vascular Reactivity in the Fructose-Induced Hypertensive Rat. Hypertension, 26, 1074-1078. https://doi.org/10.1161/01.HYP.26.6.1074
[10]
Kaplan, N.M. (1992) Effects of Antihypertensive Therapy on Insulin Resistance. Hypertension, 19, I-116-I-118. https://doi.org/10.1161/01.HYP.19.1_Suppl.I116
[11]
Klauser, R., Prager, R., Gaube, S., Gisinger, C., Schnack, C., Küenburg, E. and Schernthaner, G. (1991) Metabolic Effects of Isradipine versus Hydrochlorothiazide in Diabetes Mellitus. Hypertension, 17, 15-21. https://doi.org/10.1161/01.HYP.17.1.15
[12]
Sheu, W.H., Swislocki, A.M., Hoffman, B., Chen, Y.D. and Reaven, G.M. (1991) Comparison of the Effects of Atenolol and Nifedipine on Glucose, Insulin, and Lipid Metabolism in Patients with Hypertension. American Journal of Hypertension, 4, 199-205. https://doi.org/10.1093/ajh/4.3.199
[13]
Hwang, I.S., Ho, H.E., Hoffman, B.B. and Reaven, G.M. (1987) Fructose-Induced Insulin Resistance and Hypertension in Rats. Hypertension, 10, 512-516. https://doi.org/10.1161/01.HYP.10.5.512
[14]
Dai, S. and McNeill, J.H. (1995) Fructose-Induced Hypertension in Rats Is Concentration and Duration-Dependent. Journal of Pharmacological and Toxicological Methods, 33, 101-107. https://doi.org/10.1016/1056-8719(94)00063-A
[15]
Bergmeyer, H.U. and Bernt, E. (1974) Determination of Glucose with Glucose Oxidase and Peroxidase. Methods of Enzymatic Analysis, 2, 1205-1215.
[16]
Morton, D.B., Abbot, D., Barclay, R., Close, B.S., Ewbank, R., Gask, D., Heath, M., Mattic, S., Poole, T., Seamer, J. and Southee, J. (1993) Removal of Blood from Laboratory Mammals and Birds. Laboratory Animals, 27, 1-22. https://doi.org/10.1258/002367793781082412
[17]
Fukuyama, N., Homma, K., Wakana, N., Kudo, K., Suyama, A., Ohazama, H., Tsuji, C., Ishiwata, K., Eguchi, Y., Nakazawa, H. and Tanaka, E. (2008) Validation of the Friedewald Equation for Evaluation of Plasma LDL-Cholesterol. Journal of Clinical Biochemistry and Nutrition, 43, 1-5. https://doi.org/10.3164/jcbn.2008036
[18]
Verma, S., Bhanot, S. and McNeill, J. (1994) Antihypertensive Effects of Metformin in Fructose-Fed Hyperinsulinemic, Hypertensive Rats. Journal of Pharmacology and Experimental Therapeutics, 271, 1334-1337.
[19]
Kito, T., Shibata, R., Kondo, M., Yamamoto, T., Suzuki, H., Ishii, M. and Murohara, T. (2012) Nifedipine Ameliorates Ischemia-Induced Revascularization in Diet-Induced Obese Mice. American Journal of Hypertension, 25, 401-406. https://doi.org/10.1038/ajh.2011.239
[20]
Navarro-Cid, J., Maeso, R., Perez-Vizcaino, F., Casal, M.C., Cachofeiro, V., Ruilope, L.M. and Lahera, V. (1996) Effects of Antihypertensive Drugs on Blood Pressure and Metabolic Alterations in the Fructose-Induced Hypertensive Rat. American Journal of hypertension, 9, 669-674. https://doi.org/10.1016/0895-7061(96)00024-6
[21]
Pepine, C.J., Handberg, E.M., Cooper-DeHoff, R.M., Marks, R.G., Kowey, P., Messerli, F.H., Mancia, G., Cangiano, J.L., Garcia-Barreto, D., Keltai, M. and Erdine, S. (2003) A Calcium Antagonist vs. a Non-Calcium Antagonist Hypertension Treatment Strategy for Patients with Coronary Artery Disease: The International Verapamil-Trandolapril Study (INVEST): A Randomized Controlled Trial. JAMA, 290, 2805-1286. https://doi.org/10.1001/jama.290.21.2805
[22]
Masuo, K., Kawaguchi, H., Mikami, H., Ogihara, T. and Tuck, M.L. (2003) Serum Uric Acid and Plasma Norepinephrine Concentrations Predict Subsequent Weight Gain and Blood Pressure Elevation. Hypertension, 42, 474-480. https://doi.org/10.1161/01.HYP.0000091371.53502.D3
[23]
Sobal, G., Menzel, E.J. and Sinzinger, H. (2001) Calcium Antagonists as Inhibitors of in Vitro Low Density Lipoprotein Oxidation and Glycation. Biochemical Pharmacology, 61, 373-379. https://doi.org/10.1016/S0006-2952(00)00548-7
[24]
Bocarsly, M.E., Powell, E.S., Avena, N.M. and Hoebel, B.G. (2010) High-Fructose Corn Syrup Causes Characteristics of Obesity in Rats: Increased Body Weight, Body Fat and Triglyceride Levels. Pharmacology Biochemistry and Behavior, 97, 101-106. https://doi.org/10.1016/j.pbb.2010.02.012
[25]
Girard, A., Sihem, M., Boukortt, F., Cherkaoui-Malki, M., Belleville, J. and Prost, J. (2006) Fructose-Enriched Diet Modifies Antioxidant Status and Lipid Metabolism in Spontaneous Hypertensive Rats. Nutrition, 22, 758-766. https://doi.org/10.1016/j.nut.2006.05.006
[26]
Kaur, M., Kaur, K., Bedi, G.K., Sidhu, G.S. and Sikand, R. (2000) Effect of Felodipine on the Serum Lipid Profile of Patients with Hypertension. Indian Journal of Clinical Biochemistry, 15, 63-67. https://doi.org/10.1007/BF02883730
[27]
Eltingh, O.P. and Hajjar, D.P. (1985) Nifedipine Increases Cholesteryl Ester Hydrolytic Activity in Lipid Laden Arterial Smooth Muscle Cells. Journal of Clinical Investigation, 15, 1554-1558.
[28]
Klein, W.W. (1984) Treatment of Hypertension with Calcium Channel Blockers-European Data. American Journal of Medicine, 76, 143-146. https://doi.org/10.1016/S0002-9343(84)80050-9
[29]
Fillipovic, I. and Buddecke, E. (1986) Calcium Channel Blockers Stimulate LDL Receptor Synthesis in Human Skin Fibroblasts. Biochemical and Biophysical Research Communications, 136, 845-850. https://doi.org/10.1016/0006-291X(86)90409-2
[30]
Nakagawa, T., Tuttle, K.R., Short, R.A. and Johnson, R.J. (2005) Hypothesis: Fructose-Induced Hyperuricemia as a Causal Mechanism for the Epidemic of the Metabolic Syndrome. Nature Clinical Practice Nephrology, 1, 80-86. https://doi.org/10.1038/ncpneph0019
[31]
Nakagawa, T., Hu, H., Zharikov, S., Tuttle, K.R., Short, R.A., Glushakova, O., Ouyang, X., Feig, D.I., Block, E.R., Herrera-Acosta, J., Patel, J.M. and Johnson, R.J. (2006) A Casual for Uric Acid in Fructose Induced Metabolic Syndrome. American Journal of Physiology-Renal Physiology, 290, F625-F631. https://doi.org/10.1152/ajprenal.00140.2005
[32]
Haebisch, E.B. (1988) Nifedipine, Its Action on the Cationic Concentrations in Heart, Vessels, Skeletal Muscle and Blood in Tissues of Normotensive and Spontaneously Hypertensive Rats (SHR). General Pharmacology: The Vascular System, 19, 407-416. https://doi.org/10.1016/0306-3623(88)90038-9
[33]
Friel, K. (2004) The Effects and Interactions of Vitamin D Deficiency, Calcium and Parathyroid Hormone on Physical Concerns in the Elderly: A Review. Journal of Geriatric Physical Therapy, 27, 30-34. https://doi.org/10.1519/00139143-200404000-00005
[34]
Wollheim, C.B. and Sharp, G.W. (1981) Regulation of Insulin Release by Calcium. Physiological Reviews, 61, 914-973. https://doi.org/10.1152/physrev.1981.61.4.914
[35]
Singh, A., Bhat, T.K. and Sharma, O.P. (2011) Clinical Biochemistry of Hepatotoxicity. Journal of Clinical Toxicology, S4, 001.
[36]
Okwa, I.B., Akindele, A.J., Agbaje, E.O., Oshinuga, O.T., Anunobi, C.C. and Adeyemi, O.O. (2013) Effect of Subclinical, Clinical and Supraclinical Doses of Calcium Channel Blockers on Models of Drug-Induced Hepatotoxicity in Rats. EXCLI Journal, 12, 231-250.
